# Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

> **NCT06101342** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 181 (actual)

## Conditions studied

- Pre-Exposure Prophylaxis of HIV Infection

## Interventions

- **DRUG:** Lenacapavir Injection
- **DRUG:** Lenacapavir Tablet
- **DRUG:** Emtricitabine/tenofovir disoproxil fumarate (F/TDF)

## Key facts

- **NCT ID:** NCT06101342
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-13
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06101342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06101342, "Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06101342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*